NYSE:MRKMerck & Co., Inc. Stock Price, Forecast & News

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MRK shares have decreased by 0.6% and is now trading at $78.78. View which stocks have been most impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Merck & Co., Inc..

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Friday, July 31st 2020. View our earnings forecast for Merck & Co., Inc..

Merck & Co., Inc. will be holding an earnings conference call on Friday, July 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Merck & Co., Inc. (NYSE:MRK) posted its earnings results on Tuesday, April, 28th. The company reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.16. The business earned $12.06 billion during the quarter, compared to analysts' expectations of $11.46 billion. Merck & Co., Inc. had a return on equity of 52.46% and a net margin of 21.10%. The firm's revenue for the quarter was up 11.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.22 EPS. View Merck & Co., Inc.'s earnings history.

Merck & Co., Inc. declared a quarterly dividend on Tuesday, May 26th. Investors of record on Monday, June 15th will be given a dividend of $0.61 per share on Tuesday, July 7th. This represents a $2.44 annualized dividend and a dividend yield of 3.10%. The ex-dividend date is Friday, June 12th. View Merck & Co., Inc.'s dividend history.

Merck & Co., Inc. announced that its Board of Directors has approved a stock buyback program on Thursday, October 25th 2018, which permits the company to repurchase $10,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to reacquire up to 5.1% of its shares through open market purchases. Shares repurchase programs are often a sign that the company's board believes its shares are undervalued.

Merck & Co., Inc. updated its FY 2020 Pre-Market earnings guidance on Tuesday, April, 28th. The company provided earnings per share (EPS) guidance of 5.17-5.37 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.56. The company issued revenue guidance of $46.1-48.1 billion, compared to the consensus revenue estimate of $48.72 billion.

13 brokerages have issued twelve-month price objectives for Merck & Co., Inc.'s shares. Their forecasts range from $89.00 to $105.00. On average, they expect Merck & Co., Inc.'s stock price to reach $94.15 in the next year. This suggests a possible upside of 19.5% from the stock's current price. View analysts' price targets for Merck & Co., Inc..

Media headlines about MRK stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Merck & Co., Inc. earned a media sentiment score of -2.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the immediate future. View the latest news about Merck & Co., Inc..

Merck & Co., Inc. saw a decline in short interest during the month of June. As of June 30th, there was short interest totaling 14,560,000 shares, a decline of 7.9% from the June 15th total of 15,810,000 shares. Based on an average daily volume of 11,610,000 shares, the short-interest ratio is presently 1.3 days. Approximately 0.6% of the company's shares are sold short. View Merck & Co., Inc.'s Current Options Chain.

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Walt Disney (DIS), Cisco Systems (CSCO), JPMorgan Chase & Co. (JPM), Verizon Communications (VZ), AbbVie (ABBV) and Exxon Mobil (XOM).

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Merck & Co., Inc.'s stock is owned by a variety of institutional and retail investors. Top institutional investors include Cacti Asset Management LLC (0.03%), Park National Corp OH (0.01%), First Financial Bank Trust Division (0.00%), Thomasville National Bank (0.00%), Cox Capital Mgt LLC (0.00%) and Gantzert Investment Co. LLC ADV (0.00%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, Ashley Watson, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Leslie A Brun, Merck & Co, Inc, Richard R Deluca, Rita A Karachun, Robert M Davis, Roger M Perlmutter, Sanat Chattopadhyay, Thomas H Glocer and Wendell P Weeks. View institutional ownership trends for Merck & Co., Inc..

MRK stock was sold by a variety of institutional investors in the last quarter, including Cacti Asset Management LLC, Park National Corp OH, M&R Capital Management Inc., First Financial Bank Trust Division, and Nelson Van Denburg & Campbell Wealth Management Group LLC. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Julie L Gerberding, Richard R Deluca, and Wendell P Weeks. View insider buying and selling activity for Merck & Co., Inc..

MRK stock was bought by a variety of institutional investors in the last quarter, including Red Spruce Capital LLC, Cox Capital Mgt LLC, Gantzert Investment Co. LLC ADV, Thomasville National Bank, Modus Advisors LLC, and Ellenbecker Investment Group. View insider buying and selling activity for Merck & Co., Inc..

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRK stock can currently be purchased for approximately $78.78.

Merck & Co., Inc. has a market capitalization of $198.85 billion and generates $46.84 billion in revenue each year. The company earns $9.84 billion in net income (profit) each year or $5.19 on an earnings per share basis. Merck & Co., Inc. employs 71,000 workers across the globe.

The official website for Merck & Co., Inc. is www.merck.com.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]